|
Almeida Capital is pleased to be a premier sponsor of AltAssets
|
FREE newsletter RSS
INTELLIGENCE
RECRUITMENT
KNOWLEDGE BANK
EVENTS
SECTOR ANALYSIS
HEDGE FUNDS
|
Click here for printer friendly page
Advent Venture Partners appoints Dr Richard Mason as executive-in-residence01/05/2007. Source: AltAssets. 
 UK venture capital firm Advent Venture Partners has appointed Dr Richard Mason as executive-in-residence. Dr Mason will work with life sciences companies in the firm's portfolio.
He joins Advent Ventures from Cambridge Antibody Technology, where he was senior vice president, business development and commercial operations. Prior to CAT, Dr Mason co-founded e-health company Cambridge Health Informatics.
Dr Raj Parekh, Advent Ventures general partner, said, 'We are delighted to have Richard join the team as part of our plan to add resources and skills to help our portfolio companies succeed. His outstanding track record in business development will be a major asset for many of our portfolio companies.'
With £500m of capital under management, Advent Ventures invests in both the life science and the technology sectors.
Recent investments by the life sciences team include Norwegian radiopharmaceuticals company Algeta; US speciality pharma company CardioKine; US medical device company NeoGuide; UK-based Thiakis, which develops hormone-based treatments for obesity; the Swiss therapeutic antibody company 4-Antibody; and specialty pharmaceutical company EUSA Pharma.
Copyright © 2007 AltAssets
|
 
|
|
|
